<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03856164</url>
  </required_header>
  <id_info>
    <org_study_id>STU-2018-0315</org_study_id>
    <nct_id>NCT03856164</nct_id>
  </id_info>
  <brief_title>Tranexamic Acid for Prevention of Hemorrhage in Cesarean Delivery</brief_title>
  <acronym>TXA</acronym>
  <official_title>Use of Tranexamic Acid for Prevention of Hemorrhage in Cesarean Delivery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators prepared a novel study of tranexamic acid (TXA) designed to estimate the&#xD;
      quantity of blood loss in women undergoing elective repeat cesarean deliveries. This is the&#xD;
      first trial to utilize a prophylactic dose of TXA prior to incision followed by a subsequent&#xD;
      prophylactic dose at placental delivery in obstetric patients undergoing scheduled cesareans.&#xD;
      The purpose of this study is to quantify blood loss during uncomplicated repeat cesarean&#xD;
      deliveries with and without TXA. The central hypothesis is that TXA administration reduces&#xD;
      blood loss and fibrinolysis in women undergoing repeat cesarean sections.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Obstetric hemorrhage has been identified as a contributory cause for the United States'&#xD;
      suboptimal and inequitable outcomes among pregnant women. As such, obstetric hemorrhage has&#xD;
      become a formal focus point in a national agenda to improve maternal outcomes. Strategies to&#xD;
      identify maternal hypovolemia and treating obstetric hemorrhage are undergoing organized&#xD;
      scrutiny in many states including Texas. Tranexamic acid (TXA) treatment is receiving&#xD;
      increased emphasis in obstetric care because TXA inhibits fibrinolysis. Increased clot&#xD;
      stability offers the possibility of preventing blood loss (prophylaxis) as well as mitigating&#xD;
      ongoing hemorrhage. TXA therapy has been principally studied in nonpregnant populations;&#xD;
      results of studies in pregnant women have been lacking.&#xD;
&#xD;
      Tranexamic acid is an antifibrinolytic agent that acts as a competitive inhibitor at the&#xD;
      lysine binding sites of plasminogen and inhibits the ability of protease plasmin to cleave&#xD;
      the fibrin clot. In large randomized controlled trials, it has been reported to be effective&#xD;
      in decreasing perioperative blood loss in a variety of circumstances primarily involving&#xD;
      trauma patients. Shakur and co-authors in a trial of 20,000 non-pregnant trauma patients&#xD;
      reported a significant reduction in all-cause mortality after TXA administration. In another&#xD;
      large study (WOMAN Trial), 20,000 pregnant women with hemorrhage were randomized to TXA or&#xD;
      placebo. TXA was associated with a significant decrease in death due to bleeding.&#xD;
&#xD;
      Tranexamic acid's role in treating hemorrhage have been widely studied in non-pregnant&#xD;
      populations. Studies of TXA in obstetrics are limited. The American College of Obstetricians&#xD;
      and Gynecologists believes the data is insufficient to recommend tranexamic acid for&#xD;
      prophylaxis.&#xD;
&#xD;
      The investigators designed a randomized placebo-controlled trial comparing TXA dosing prior&#xD;
      to incision for cesarean delivery with a repeat dose given at placental delivery. The purpose&#xD;
      is to quantify blood loss during uncomplicated repeat cesarean deliveries with and without&#xD;
      TXA. The investigators elected to study scheduled elective cesareans because such procedures&#xD;
      are at low risk for profound hemorrhage. It is the intent to have a study cohort where the&#xD;
      two treatment groups (TXA or placebo) are as comparable as possible, so the efficacy of TXA&#xD;
      is not tested in women with highly variable volumes of obstetric hemorrhage.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 17, 2019</start_date>
  <completion_date type="Actual">August 31, 2020</completion_date>
  <primary_completion_date type="Actual">January 10, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood Volume Loss</measure>
    <time_frame>24 hours postpartum.</time_frame>
    <description>Total blood volume loss will be calculated in milliliters.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>D-Dimer (µg/mL)</measure>
    <time_frame>Collection prior to first drug infusion, immediately before second infusion and 24 hours postpartum.</time_frame>
    <description>Measured from blood sample collection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrinogen (mg/dL)</measure>
    <time_frame>Collection prior to first drug infusion, immediately before second infusion and 24 hours postpartum.</time_frame>
    <description>Measured from blood sample collection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tissue Plasminogen Activator Antigen (ng/mL)</measure>
    <time_frame>Collection prior to first drug infusion, immediately before second infusion and 24 hours postpartum.</time_frame>
    <description>Measured from blood sample collection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasminogen Activator Inhibitor-Type-1 (Units/mL)</measure>
    <time_frame>Collection prior to first drug infusion, immediately before second infusion and 24 hours postpartum.</time_frame>
    <description>Measured from blood sample collection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rotational Thromboelastometry INTEM and EXTEM Clotting Time</measure>
    <time_frame>Collection prior to first drug infusion, immediately before second infusion and 24 hours postpartum.</time_frame>
    <description>Rotational thromboelastometry is a whole blood viscoelastic test that analyzes deficits in clotting factors, clot strength, and clot breakdown. EXTEM, INTEM, and FIBTEM tests measure the extrinsic pathway, intrinsic pathway, and fibrinogen levels, respectively. Compared to non-pregnant patients, FIBTEM/EXTEM/INTEM amplitudes and the FIBTEM maximum clot firmness are higher in pregnant women. The EXTEM and INTEM clotting time are shorter, indicating the relative hypercoagulability of pregnancy. Reference ranges for INTEM Clotting Time (100-240 seconds), INTEM Maximum Clot Firmness (50-72 millimeter), EXTEM Clotting Time (38-79 seconds), EXTEM Maximum Clot Firmness (50-72 millimeter), FIBTEM Maximum Clot Firmness (9-25 millimeter).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rotational Thromboelastometry INTEM, EXTEM, FIBTEM Maximum Clot Firmness</measure>
    <time_frame>Collection prior to first drug infusion, immediately before second infusion and 24 hours postpartum.</time_frame>
    <description>Rotational thromboelastometry is a whole blood viscoelastic test that analyzes deficits in clotting factors, clot strength, and clot breakdown. EXTEM, INTEM, and FIBTEM tests measure the extrinsic pathway, intrinsic pathway, and fibrinogen levels, respectively. Compared to non-pregnant patients, FIBTEM/EXTEM/INTEM amplitudes and the FIBTEM maximum clot firmness are higher in pregnant women. The EXTEM and INTEM clotting time are shorter, indicating the relative hypercoagulability of pregnancy. Reference ranges for INTEM Clotting Time (100-240 seconds), INTEM Maximum Clot Firmness (50-72 millimeter), EXTEM Clotting Time (38-79 seconds), EXTEM Maximum Clot Firmness (50-72 millimeter), FIBTEM Maximum Clot Firmness (9-25 millimeter).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Post Partum Hemorrhage</condition>
  <condition>Fibrinolysis; Hemorrhage</condition>
  <condition>Blood Loss</condition>
  <arm_group>
    <arm_group_label>Tranexamic acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tranexamic Acid for intravenous administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline for intravenous administration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>Two doses of Tranexamic Acid (1 gram), diluted in 100 cc of normal saline. Administered intravenously at least 10 minutes prior to skin incision and repeated immediately after placental delivery.</description>
    <arm_group_label>Tranexamic acid</arm_group_label>
    <other_name>Cyklokapron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>100 mL of normal saline. Administered intravenously at least 10 minutes prior to skin incision and repeated immediately after placental delivery.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Normal Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Intrauterine pregnancy&#xD;
&#xD;
          2. Age ≥ 18&#xD;
&#xD;
          3. Gestation age ≥ 37 weeks 0 days&#xD;
&#xD;
          4. Scheduled cesarean delivery&#xD;
&#xD;
          5. Second or third cesarean delivery&#xD;
&#xD;
          6. Singleton pregnancy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. First cesarean delivery&#xD;
&#xD;
          2. Four or more cesarean deliveries&#xD;
&#xD;
          3. Intrauterine fetal death&#xD;
&#xD;
          4. Fetal anomalies&#xD;
&#xD;
          5. Documented coagulopathy (Elevated Prothrombin Time (PT), Elevated Partial&#xD;
             Thromboplastin Time (PTT), Elevated International Normalized Ratio (INR))&#xD;
&#xD;
          6. Thrombocytopenia (Platelet count &lt; 100k)&#xD;
&#xD;
          7. Internal bleeding, external bleeding, easy bruising&#xD;
&#xD;
          8. History of thrombotic event&#xD;
&#xD;
          9. Hypertension&#xD;
&#xD;
         10. Diagnosis of renal insufficiency (Creatinine&gt; 1 mg/dL)&#xD;
&#xD;
         11. Insulin-treated diabetes&#xD;
&#xD;
         12. Suspected morbidly adherent placenta&#xD;
&#xD;
         13. Placenta previa&#xD;
&#xD;
         14. Multiple Gestations&#xD;
&#xD;
         15. BMI ≥ 50&#xD;
&#xD;
         16. Hematocrit ≤ 25&#xD;
&#xD;
         17. Blood transfusion within 24 hours prior to cesarean delivery&#xD;
&#xD;
         18. History of abnormal bleeding or blood disorder&#xD;
&#xD;
         19. Planned general anesthesia&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olutoyosi Ogunkua, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Parkland Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>American Society of Anesthesiologists Task Force on Perioperative Blood Management. Practice guidelines for perioperative blood management: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Management*. Anesthesiology. 2015 Feb;122(2):241-75. doi: 10.1097/ALN.0000000000000463. Review.</citation>
    <PMID>25545654</PMID>
  </reference>
  <reference>
    <citation>WHO Recommendations for the Prevention and Treatment of Postpartum Haemorrhage. Geneva: World Health Organization; 2012.</citation>
    <PMID>23586122</PMID>
  </reference>
  <reference>
    <citation>Carroli G, Cuesta C, Abalos E, Gulmezoglu AM. Epidemiology of postpartum haemorrhage: a systematic review. Best Pract Res Clin Obstet Gynaecol. 2008 Dec;22(6):999-1012. doi: 10.1016/j.bpobgyn.2008.08.004. Epub 2008 Sep 25. Review.</citation>
    <PMID>18819848</PMID>
  </reference>
  <reference>
    <citation>GBD 2015 Maternal Mortality Collaborators. Global, regional, and national levels of maternal mortality, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016 Oct 8;388(10053):1775-1812. doi: 10.1016/S0140-6736(16)31470-2. Erratum in: Lancet. 2017 Jan 7;389(10064):e1.</citation>
    <PMID>27733286</PMID>
  </reference>
  <reference>
    <citation>WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet. 2017 May 27;389(10084):2105-2116. doi: 10.1016/S0140-6736(17)30638-4. Epub 2017 Apr 26. Erratum in: Lancet. 2017 May 27;389(10084):2104.</citation>
    <PMID>28456509</PMID>
  </reference>
  <reference>
    <citation>Committee on Practice Bulletins-Obstetrics. Practice Bulletin No. 183: Postpartum Hemorrhage. Obstet Gynecol. 2017 Oct;130(4):e168-e186. doi: 10.1097/AOG.0000000000002351.</citation>
    <PMID>28937571</PMID>
  </reference>
  <reference>
    <citation>Ducloy-Bouthors AS, Jeanpierre E, Saidi I, Baptiste AS, Simon E, Lannoy D, Duhamel A, Allorge D, Susen S, Hennart B. TRAnexamic acid in hemorrhagic CESarean section (TRACES) randomized placebo controlled dose-ranging pharmacobiological ancillary trial: study protocol for a randomized controlled trial. Trials. 2018 Mar 1;19(1):149. doi: 10.1186/s13063-017-2421-6.</citation>
    <PMID>29490690</PMID>
  </reference>
  <reference>
    <citation>Dunn CJ, Goa KL. Tranexamic acid: a review of its use in surgery and other indications. Drugs. 1999 Jun;57(6):1005-32. Review.</citation>
    <PMID>10400410</PMID>
  </reference>
  <reference>
    <citation>Hernandez JS, Alexander JM, Sarode R, McIntire DD, Leveno KJ. Calculated blood loss in severe obstetric hemorrhage and its relation to body mass index. Am J Perinatol. 2012 Aug;29(7):557-60. doi: 10.1055/s-0032-1310528. Epub 2012 Apr 11.</citation>
    <PMID>22495893</PMID>
  </reference>
  <reference>
    <citation>Huissoud C, Carrabin N, Audibert F, Levrat A, Massignon D, Berland M, Rudigoz RC. Bedside assessment of fibrinogen level in postpartum haemorrhage by thrombelastometry. BJOG. 2009 Jul;116(8):1097-102. doi: 10.1111/j.1471-0528.2009.02187.x. Epub 2009 May 12.</citation>
    <PMID>19459866</PMID>
  </reference>
  <reference>
    <citation>Khan KS, Wojdyla D, Say L, Gülmezoglu AM, Van Look PF. WHO analysis of causes of maternal death: a systematic review. Lancet. 2006 Apr 1;367(9516):1066-1074. doi: 10.1016/S0140-6736(06)68397-9. Review.</citation>
    <PMID>16581405</PMID>
  </reference>
  <reference>
    <citation>Main EK, Goffman D, Scavone BM, Low LK, Bingham D, Fontaine PL, Gorlin JB, Lagrew DC, Levy BS; National Partnership for Maternal Safety; Council on Patient Safety in Women's Health Care. National Partnership for Maternal Safety: Consensus Bundle on Obstetric Hemorrhage. Obstet Gynecol. 2015 Jul;126(1):155-62. doi: 10.1097/AOG.0000000000000869. Erratum in: Obstet Gynecol. 2015 Nov;126(5):1111. Obstet Gynecol. 2019 Jun;133(6):1288.</citation>
    <PMID>26241269</PMID>
  </reference>
  <reference>
    <citation>McCormack PL. Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis. Drugs. 2012 Mar 26;72(5):585-617. doi: 10.2165/11209070-000000000-00000. Review.</citation>
    <PMID>22397329</PMID>
  </reference>
  <reference>
    <citation>Molina RL, Pace LE. A Renewed Focus on Maternal Health in the United States. N Engl J Med. 2017 Nov 2;377(18):1705-1707. doi: 10.1056/NEJMp1709473.</citation>
    <PMID>29091560</PMID>
  </reference>
  <reference>
    <citation>Say L, Chou D, Gemmill A, Tunçalp Ö, Moller AB, Daniels J, Gülmezoglu AM, Temmerman M, Alkema L. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health. 2014 Jun;2(6):e323-33. doi: 10.1016/S2214-109X(14)70227-X. Epub 2014 May 5. Review.</citation>
    <PMID>25103301</PMID>
  </reference>
  <reference>
    <citation>John M. Eisenberg Center for Clinical Decisions and Communications Science. Management of Postpartum Hemorrhage: Current State of the Evidence. 2016 Jul 12. Comparative Effectiveness Review Summary Guides for Clinicians [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2007-. Available from http://www.ncbi.nlm.nih.gov/books/NBK379234/</citation>
    <PMID>27512800</PMID>
  </reference>
  <reference>
    <citation>Sentilhes L, Winer N, Azria E, Sénat MV, Le Ray C, Vardon D, Perrotin F, Desbrière R, Fuchs F, Kayem G, Ducarme G, Doret-Dion M, Huissoud C, Bohec C, Deruelle P, Darsonval A, Chrétien JM, Seco A, Daniel V, Deneux-Tharaux C; Groupe de Recherche en Obstétrique et Gynécologie. Tranexamic Acid for the Prevention of Blood Loss after Vaginal Delivery. N Engl J Med. 2018 Aug 23;379(8):731-742. doi: 10.1056/NEJMoa1800942.</citation>
    <PMID>30134136</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>February 21, 2019</study_first_submitted>
  <study_first_submitted_qc>February 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2019</study_first_posted>
  <results_first_submitted>November 11, 2020</results_first_submitted>
  <results_first_submitted_qc>January 12, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 19, 2021</results_first_posted>
  <last_update_submitted>January 12, 2021</last_update_submitted>
  <last_update_submitted_qc>January 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Olutoyosi Ogunkua, MD</investigator_full_name>
    <investigator_title>Assistant Professor of Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>Tranexamic acid</keyword>
  <keyword>TXA</keyword>
  <keyword>Anti-fibrinolytics</keyword>
  <keyword>Postpartum hemorrhage</keyword>
  <keyword>Obstetric hemorrhage</keyword>
  <keyword>Fibrinolysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Postpartum Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 13, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/64/NCT03856164/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 13, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/64/NCT03856164/SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 13, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/64/NCT03856164/ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited based on admission for delivery at an academic center between June 2019 and January 2020. The first participant was enrolled on June 17, 2019, and the last participant was enrolled on January 10, 2020.</recruitment_details>
      <pre_assignment_details>Of the 110 enrolled participants, all met inclusion criteria and were randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Tranexamic Acid</title>
          <description>Participants received two doses (1 gram) of tranexamic acid diluted in 100 mL of normal saline. Tranexamic acid was given intravenously at least 10 minutes prior to skin incision and repeated immediately after placental delivery.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participants received 100 mL of normal saline. Administered intravenously at least 10 minutes prior to skin incision and repeated immediately after placental delivery.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tranexamic Acid</title>
          <description>Tranexamic Acid for intravenous administration.&#xD;
Tranexamic Acid: Two doses of Tranexamic Acid (1 gram), diluted in 100 cc of normal saline. Administered intravenously at least 10 minutes prior to skin incision and repeated immediately after placental delivery.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Normal saline for intravenous administration.&#xD;
Placebo: 100 mL of normal saline. Administered intravenously at least 10 minutes prior to skin incision and repeated immediately after placental delivery.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="55"/>
            <count group_id="B2" value="55"/>
            <count group_id="B3" value="110"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.8" spread="5.2"/>
                    <measurement group_id="B2" value="28.7" spread="5.2"/>
                    <measurement group_id="B3" value="29.3" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="110"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Black, non-Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White, non-Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Parity</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Parity = 1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Parity = 2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Parity = 3</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Parity = 4</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Parity = 5</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (kg/m^2)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt; 25</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>25 - &lt; 30</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>30 - &lt; 35</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>35 - &lt; 40</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt; =40</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Blood Volume Loss</title>
        <description>Total blood volume loss will be calculated in milliliters.</description>
        <time_frame>24 hours postpartum.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tranexamic Acid</title>
            <description>Participants received two doses (1 gram) of tranexamic acid diluted in 100 mL of normal saline. Tranexamic acid was given intravenously at least 10 minutes prior to skin incision and repeated immediately after placental delivery.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received 100 mL of normal saline. Administered intravenously at least 10 minutes prior to skin incision and repeated immediately after placental delivery.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Volume Loss</title>
          <description>Total blood volume loss will be calculated in milliliters.</description>
          <units>milliliters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2274" spread="469"/>
                    <measurement group_id="O2" value="2407" spread="388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>D-Dimer (µg/mL)</title>
        <description>Measured from blood sample collection.</description>
        <time_frame>Collection prior to first drug infusion, immediately before second infusion and 24 hours postpartum.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tranexamic Acid</title>
            <description>Participants received two doses (1 gram) of tranexamic acid diluted in 100 mL of normal saline. Tranexamic acid was given intravenously at least 10 minutes prior to skin incision and repeated immediately after placental delivery.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received 100 mL of normal saline. Administered intravenously at least 10 minutes prior to skin incision and repeated immediately after placental delivery.</description>
          </group>
        </group_list>
        <measure>
          <title>D-Dimer (µg/mL)</title>
          <description>Measured from blood sample collection.</description>
          <units>µg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before Surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="1.5"/>
                    <measurement group_id="O2" value="4.0" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Delivery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="1.3"/>
                    <measurement group_id="O2" value="3.8" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P.O.D. 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="1.2"/>
                    <measurement group_id="O2" value="4.3" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fibrinogen (mg/dL)</title>
        <description>Measured from blood sample collection.</description>
        <time_frame>Collection prior to first drug infusion, immediately before second infusion and 24 hours postpartum.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tranexamic Acid</title>
            <description>Participants received two doses (1 gram) of tranexamic acid diluted in 100 mL of normal saline. Tranexamic acid was given intravenously at least 10 minutes prior to skin incision and repeated immediately after placental delivery.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received 100 mL of normal saline. Administered intravenously at least 10 minutes prior to skin incision and repeated immediately after placental delivery.</description>
          </group>
        </group_list>
        <measure>
          <title>Fibrinogen (mg/dL)</title>
          <description>Measured from blood sample collection.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before Surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="563.5" spread="83.9"/>
                    <measurement group_id="O2" value="550.7" spread="68.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Delivery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="499.6" spread="77"/>
                    <measurement group_id="O2" value="484.9" spread="82.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P.O.D. 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="527.4" spread="69.8"/>
                    <measurement group_id="O2" value="525.4" spread="86.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tissue Plasminogen Activator Antigen (ng/mL)</title>
        <description>Measured from blood sample collection.</description>
        <time_frame>Collection prior to first drug infusion, immediately before second infusion and 24 hours postpartum.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tranexamic Acid</title>
            <description>Participants received two doses (1 gram) of tranexamic acid diluted in 100 mL of normal saline. Tranexamic acid was given intravenously at least 10 minutes prior to skin incision and repeated immediately after placental delivery.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received 100 mL of normal saline. Administered intravenously at least 10 minutes prior to skin incision and repeated immediately after placental delivery.</description>
          </group>
        </group_list>
        <measure>
          <title>Tissue Plasminogen Activator Antigen (ng/mL)</title>
          <description>Measured from blood sample collection.</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before Surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" spread="3.6"/>
                    <measurement group_id="O2" value="8.2" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Delivery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" spread="3.7"/>
                    <measurement group_id="O2" value="9.6" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P.O.D. 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" spread="3.7"/>
                    <measurement group_id="O2" value="7.4" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasminogen Activator Inhibitor-Type-1 (Units/mL)</title>
        <description>Measured from blood sample collection.</description>
        <time_frame>Collection prior to first drug infusion, immediately before second infusion and 24 hours postpartum.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tranexamic Acid</title>
            <description>Tranexamic Acid for intravenous administration.&#xD;
Tranexamic Acid: Two doses of Tranexamic Acid (1 gram), diluted in 100 cc of normal saline. Administered intravenously at least 10 minutes prior to skin incision and repeated immediately after placental delivery.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Normal saline for intravenous administration.&#xD;
Placebo: 100 mL of normal saline. Administered intravenously at least 10 minutes prior to skin incision and repeated immediately after placental delivery.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasminogen Activator Inhibitor-Type-1 (Units/mL)</title>
          <description>Measured from blood sample collection.</description>
          <units>IU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before Surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.8" spread="34.7"/>
                    <measurement group_id="O2" value="61.7" spread="33.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Delivery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.0" spread="32.3"/>
                    <measurement group_id="O2" value="63.3" spread="31.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P.O.D. 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.7" spread="26.7"/>
                    <measurement group_id="O2" value="22.1" spread="28.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rotational Thromboelastometry INTEM and EXTEM Clotting Time</title>
        <description>Rotational thromboelastometry is a whole blood viscoelastic test that analyzes deficits in clotting factors, clot strength, and clot breakdown. EXTEM, INTEM, and FIBTEM tests measure the extrinsic pathway, intrinsic pathway, and fibrinogen levels, respectively. Compared to non-pregnant patients, FIBTEM/EXTEM/INTEM amplitudes and the FIBTEM maximum clot firmness are higher in pregnant women. The EXTEM and INTEM clotting time are shorter, indicating the relative hypercoagulability of pregnancy. Reference ranges for INTEM Clotting Time (100-240 seconds), INTEM Maximum Clot Firmness (50-72 millimeter), EXTEM Clotting Time (38-79 seconds), EXTEM Maximum Clot Firmness (50-72 millimeter), FIBTEM Maximum Clot Firmness (9-25 millimeter).</description>
        <time_frame>Collection prior to first drug infusion, immediately before second infusion and 24 hours postpartum.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tranexamic Acid</title>
            <description>Tranexamic Acid for intravenous administration.&#xD;
Tranexamic Acid: Two doses of Tranexamic Acid (1 gram), diluted in 100 cc of normal saline. Administered intravenously at least 10 minutes prior to skin incision and repeated immediately after placental delivery.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Normal saline for intravenous administration.&#xD;
Placebo: 100 mL of normal saline. Administered intravenously at least 10 minutes prior to skin incision and repeated immediately after placental delivery.</description>
          </group>
        </group_list>
        <measure>
          <title>Rotational Thromboelastometry INTEM and EXTEM Clotting Time</title>
          <description>Rotational thromboelastometry is a whole blood viscoelastic test that analyzes deficits in clotting factors, clot strength, and clot breakdown. EXTEM, INTEM, and FIBTEM tests measure the extrinsic pathway, intrinsic pathway, and fibrinogen levels, respectively. Compared to non-pregnant patients, FIBTEM/EXTEM/INTEM amplitudes and the FIBTEM maximum clot firmness are higher in pregnant women. The EXTEM and INTEM clotting time are shorter, indicating the relative hypercoagulability of pregnancy. Reference ranges for INTEM Clotting Time (100-240 seconds), INTEM Maximum Clot Firmness (50-72 millimeter), EXTEM Clotting Time (38-79 seconds), EXTEM Maximum Clot Firmness (50-72 millimeter), FIBTEM Maximum Clot Firmness (9-25 millimeter).</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before Surgery INTEM Clotting Time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149.7" spread="14.4"/>
                    <measurement group_id="O2" value="150.5" spread="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Delivery INTEM Clotting Time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137.4" spread="18.3"/>
                    <measurement group_id="O2" value="140.7" spread="29.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P.O.D. 1 INTEM Clotting Time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145.1" spread="16.3"/>
                    <measurement group_id="O2" value="141.2" spread="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Surgery EXTEM Clotting Time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.0" spread="5.1"/>
                    <measurement group_id="O2" value="56.1" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Delivery EXTEM Clotting Time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.9" spread="6.3"/>
                    <measurement group_id="O2" value="56.3" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P.O.D. 1 EXTEM Clotting Time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.3" spread="5.3"/>
                    <measurement group_id="O2" value="50.2" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rotational Thromboelastometry INTEM, EXTEM, FIBTEM Maximum Clot Firmness</title>
        <description>Rotational thromboelastometry is a whole blood viscoelastic test that analyzes deficits in clotting factors, clot strength, and clot breakdown. EXTEM, INTEM, and FIBTEM tests measure the extrinsic pathway, intrinsic pathway, and fibrinogen levels, respectively. Compared to non-pregnant patients, FIBTEM/EXTEM/INTEM amplitudes and the FIBTEM maximum clot firmness are higher in pregnant women. The EXTEM and INTEM clotting time are shorter, indicating the relative hypercoagulability of pregnancy. Reference ranges for INTEM Clotting Time (100-240 seconds), INTEM Maximum Clot Firmness (50-72 millimeter), EXTEM Clotting Time (38-79 seconds), EXTEM Maximum Clot Firmness (50-72 millimeter), FIBTEM Maximum Clot Firmness (9-25 millimeter).</description>
        <time_frame>Collection prior to first drug infusion, immediately before second infusion and 24 hours postpartum.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tranexamic Acid</title>
            <description>Tranexamic Acid for intravenous administration.&#xD;
Tranexamic Acid: Two doses of Tranexamic Acid (1 gram), diluted in 100 cc of normal saline. Administered intravenously at least 10 minutes prior to skin incision and repeated immediately after placental delivery.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Normal saline for intravenous administration.&#xD;
Placebo: 100 mL of normal saline. Administered intravenously at least 10 minutes prior to skin incision and repeated immediately after placental delivery.</description>
          </group>
        </group_list>
        <measure>
          <title>Rotational Thromboelastometry INTEM, EXTEM, FIBTEM Maximum Clot Firmness</title>
          <description>Rotational thromboelastometry is a whole blood viscoelastic test that analyzes deficits in clotting factors, clot strength, and clot breakdown. EXTEM, INTEM, and FIBTEM tests measure the extrinsic pathway, intrinsic pathway, and fibrinogen levels, respectively. Compared to non-pregnant patients, FIBTEM/EXTEM/INTEM amplitudes and the FIBTEM maximum clot firmness are higher in pregnant women. The EXTEM and INTEM clotting time are shorter, indicating the relative hypercoagulability of pregnancy. Reference ranges for INTEM Clotting Time (100-240 seconds), INTEM Maximum Clot Firmness (50-72 millimeter), EXTEM Clotting Time (38-79 seconds), EXTEM Maximum Clot Firmness (50-72 millimeter), FIBTEM Maximum Clot Firmness (9-25 millimeter).</description>
          <units>millimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before Surgery INTEM Maximum Clot Firmness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.3" spread="3.3"/>
                    <measurement group_id="O2" value="69.4" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Delivery INTEM Maximum Clot Firmness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.9" spread="3.2"/>
                    <measurement group_id="O2" value="68.4" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P.O.D. 1 INTEM Maximum Clot Firmness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.8" spread="3.1"/>
                    <measurement group_id="O2" value="68.8" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Surgery EXTEM Maximum Clot Firmness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.8" spread="3.1"/>
                    <measurement group_id="O2" value="71.2" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Delivery EXTEM Maximum Clot Firmness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.8" spread="3.1"/>
                    <measurement group_id="O2" value="69.6" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P.O.D. 1 EXTEM Maximum Clot Firmness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.5" spread="2.8"/>
                    <measurement group_id="O2" value="70.4" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Surgery FIBTEM Maximum Clot Firmness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.2" spread="3.8"/>
                    <measurement group_id="O2" value="23.9" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Delivery FIBTEM Maximum Clot Firmness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.5" spread="4.1"/>
                    <measurement group_id="O2" value="22.0" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P.O.D. 1 FIBTEM Maximum Clot Firmness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.8" spread="4.7"/>
                    <measurement group_id="O2" value="25.0" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During patient admission, minimum of 3 days.</time_frame>
      <desc>Only serious adverse events were collected according to the study protocol</desc>
      <group_list>
        <group group_id="E1">
          <title>Tranexamic Acid</title>
          <description>Participants received two doses (1 gram) of tranexamic acid diluted in 100 mL of normal saline. Tranexamic acid was given intravenously at least 10 minutes prior to skin incision and repeated immediately after placental delivery.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants received 100 mL of normal saline. Administered intravenously at least 10 minutes prior to skin incision and repeated immediately after placental delivery.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Olutoyosi Ogunkua</name_or_title>
      <organization>University of Texas Southwestern</organization>
      <phone>2145578873</phone>
      <email>olutoyosi.ogunkua@utsouthwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

